chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Woke up that night with bad chills; Had low grade fever / fever kept increasing to about 102.7 F; Very tired/fatigued; Sweating a lot; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0172) via an unspecified route of administration in the left arm on 26Apr2021 at 12:30 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history included mild asthma. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included bupropion hydrochloride (WELLBUTRIN), amfetamine aspartate, amfetamine sulfate, dexamfetamine saccharate, dexamfetamine sulfate (ADDERALL), desvenlafaxine succinate monohydrate (PRISTIQ) and multivitamin (MANUFACTURER UNKNOWN); all taken for an unspecified indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the left arm on 05Apr2021 at 13:30 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. On 27Apr2021 at 02:00, the patient woke up that night with bad chills. On 27Apr2021, later that morning, the patient had low grade fever and was very tired/fatigued. Around 11:30, he took Motrin, felt better and around 15:30 felt very tired again and fever came back. He slept and fever kept increasing to about 102.7 Fahrenheit at 19:45 and around 20:30 took more Motrin. Fever came down and he was sweating a lot then after that no more fever. On 28Apr2021 (Wednesday), he felt pretty tired but was able to return to work. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of the events which included treatment with ibuprofen (MOTRIN). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events had low grade fever / fever kept increasing to about 102.7 F and sweating was resolved on 27Apr2021 while bad chills and very tired/fatigued was resolved on an unknown date in 2021.  No follow-up attempts are needed. No further information is expected.
Admission Date: 7/13/2022 Discharge Date: 07/16/2022 Discharge disposition: Home Condition on discharge: Stable.   Acute respiratory failure with hypoxia (HCC) [J96.01] Pneumonia due to COVID-19 virus [U07.1, J12.82]   ADMISSION AND DISCHARGE DIAGNOSES:  HOSPITAL COURSE:   Acute hypoxic respiratory failure. Resolved  Pneumonia due to COVID 19, improving  Possible Superimposed Bacterial pneumonia, improving  - symptom onset; positive test 7/13 - Vaccinated and boosted w/ Pfizer; did not receive second booster - Treated with Decadron, Remdesivir, Ceftriaxone and doxycycline with improvement  - 2 doses lasix today due to severe congestion with improvement  - Home on 2L O2 with activity    Elevated troponin is myocardial injury in the setting of PNA  - EKG not ischemic. ECHO is normal. No chest pain. No further workup. Monitor    Alcohol Abuse - 2-3 beers daily; no hx of withdrawal - s/p thiamine folate, multivitamin  - SW evaluated    COPD - continue home meds    Hx of Esophageal cancer   Hypothyroid - continue synthroid
This is an instance of breakthrough COVID-19 after which death occurred. The individual was vaccinated with the Pfizer product on 01/07/2021, 01/28/2021, and 10/11/2021. The individual also received a HighDoseQ influenza vaccine on 10/11/2021. They tested positive for COVID-19 on 09/21/2021 via antigen test at the hospital and were hospitalized twice around the time of the positive test: 09/06/2021-09/08/2021 and again from 09/15/2021-09/17/2021. The individual had a negative COVID-19 test on 10/06/2021 at the retirement home at which they were a resident. They presented to emergency department via ambulance on 10/13/2021, 2 days after receiving the third dose of the Pfizer product and an influenza vaccine on the same day. Primary complaints were swelling in leg, weakness, loss of appetite, and "not coming out of [their] room for 3 days." They were put on comfort care and died on 10/19/2021 in the hospital. Clinical notes indicate they had "severe COVID related CVA" prior to death, and COVID-19 pneumonia is on the death certificate, even though there was a negative COVID-19 test between the positive test and the person's death.
Shoulder injury related to vaccine administration (SIRVA) resulting in ongoing left shoulder pain, weakness and numbness of left shoulder, left upper arm, elbow,  forearm, left hand and pinky and ring finger of left hand. It happened immediately after the shot was give to administer the COVID Pfizer Vaccine. The person administering it used a technique I have never seen to administer a shot pushing with his pointer finger with his hand underneath the syringe. He didn't look that confident and it was the most painful shot I have ever had with the pain started immediately. He must have hit and damaged a nerve. It was kind of a weird appointment. I have just been hoping it will go away doing normal activities when I can and some exercises hoping it will work itself out but it has not.  I am concerned it is permanent. It hurts right now as I type and as I just leave it still. I can tell that my left hand's two outside fingers, the pinky and ring finger are numb right now as I use them to type. It's kind of sad and depressing. I would happily get the vaccine again to protect myself and other but when we when in for the second shots we steered clear of the guy who gave me the first shot that messed me up so much. The experienced nurse that gave me the second shot did a great job and I hardly felt it.
Pain in left hip and lower left back, after usual physical therapy session, acute 3 days & lasted 6 days.
103.9 temp, severe neck pain from upper back to head, stiff neck, headache, chills, excessive fatigue, dizziness,sore arm
Myalgia, Arthralgia, PAIN AT INJECTION SITE, CHILLS, FATIGUES Narrative:
Pt Rcvd vaccine @ 11am - went home - at 1 PM developed hives & itching (generalized) & shortness of breath - Mother gave child BENDRYL oral & brought to hospital ER - Start IVF's & neb treatments for asthma - D/Cod @ 4 PM
This spontaneous case reported by a patient, describes the occurrence of pyrexia (fever) in a patient, of an unknown age and gender, who received mRNA-1273 (Moderna COVID-19 vaccine) for COVID-19 immunization. No medical history reported. On an unknown date, patient received the first dose of mRNA-1273 (Moderna COVID-19 vaccine), unknown route; 1 dosage form. On an unknown date, patient experienced pyrexia (fever). At the time of the report, pyrexia (fever) outcome: unknown. The action taken with mRNA-1273 (Moderna COVID-19 vaccine): unknown. No concomitant medication or treatment information reported.
A few hours after injection, injection site became very sore, started running a fever, HA, body aches, malaise, inability to sleep well. The worst lasting for 3 days. Could not go to work. Loss of appetite.
Information has been received from a licensed practical nurse concerning a 55 year old female with hypothyroidism, chronic obstructive pulmonary disease, penicillin allergy and drug hypersensitivity to erythromycin and KEFLEX who on 30-AUG-2006 was vaccinated IM with a 0.5 ml dose of Pneumovax 23.. Concomitant therapy included SYNTHROID, CLARITIN, albuterol and calcium (+) vitamin D (unspecified). On 31-AUG-2006 the patient developed swelling and soreness of left upper arm and nausea. Unspecified medical attention was sought. There were no laboratory or diagnostic tests. The patient's outcome was unknown. Additional information has been requested.
Cheeks really red; Redness at the injection site; Chills in the middle of the night; Fever of 103; This spontaneous case was reported by a consumer and describes the occurrence of FLUSHING (Cheeks really red), VACCINATION SITE ERYTHEMA (Redness at the injection site), CHILLS (Chills in the middle of the night) and PYREXIA (Fever of 103) in a 49-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 14-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Jan-2021, the patient experienced FLUSHING (Cheeks really red), VACCINATION SITE ERYTHEMA (Redness at the injection site), CHILLS (Chills in the middle of the night) and PYREXIA (Fever of 103). The patient was treated with PARACETAMOL (TYLENOL) for Adverse event, at an unspecified dose and frequency and DEXTROMETHORPHAN HYDROBROMIDE, DOXYLAMINE SUCCINATE, EPHEDRINE SULFATE, ETHANOL, PARACETAMOL (NYQUIL) for Adverse event, at an unspecified dose and frequency. At the time of the report, FLUSHING (Cheeks really red), VACCINATION SITE ERYTHEMA (Redness at the injection site), CHILLS (Chills in the middle of the night) and PYREXIA (Fever of 103) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 14-Jan-2021, Body temperature: 103 (High) 103.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications were not provided.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Information has been received from a Licensed Practical Nurse for the Pregnancy Registry for GARDASIL vaccine, concerning a 20 year old female who on 01-MAR-2008 was vaccinated intramuscularly with a 0.5 mL first dose of GARDASIL vaccine (Lot #658556/1060U). On 19-MAY-2008 the patient was vaccinated intramuscularly with a 0.5 mL second dose of GARDASIL vaccine (lot# 660389/1968U). Concomitant therapy included AZOR. It was unspecified if the patient was "currently on" alprazolam. The patient's LMP was reported as 30-APR-2008 (estimated due date 04-FEB-2009). The patient sought unspecified medical attention during an office visit. Laboratory diagnostics studies performed on an unspecified date included an "abnormal PAP." Additional information has been requested.
patient is two months late for her second Moderna Covid-19 injection/pateint received her first dose of Moderna Covid-19 injection on 01Apr2021; This spontaneous case was reported by a health care professional (subsequently medically confirmed) and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (patient is two months late for her second Moderna Covid-19 injection/pateint received her first dose of Moderna Covid-19 injection on 01Apr2021) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 01-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form(s). On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (patient is two months late for her second Moderna Covid-19 injection/pateint received her first dose of Moderna Covid-19 injection on 01Apr2021). At the time of the report, PRODUCT DOSE OMISSION ISSUE (patient is two months late for her second Moderna Covid-19 injection/pateint received her first dose of Moderna Covid-19 injection on 01Apr2021) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported.  No laboratory details were  provided.  No treatment medications were reported.  Action taken with mRNA-1273 in response to the events was not applicable.
Systemic: Chills-Mild, Systemic: Dizziness / Lightheadness-Mild, Systemic: Fainting / Unresponsive-Mild, Systemic: Flushed / Sweating-Mild, Additional Details: Patient fainted after vaccination for about 5- 10 seconds, regained consciousness. pt was provided sugar and water. monitored for about 30 minutes. pt refused emt service. felt okay after 30 minutes and went home.
Frozen shoulder two days following the injection. The injection was administered too high in the shoulder. X-ray taken, steroid injection, and physical therapy twice a week, which still continues four months after the injection. He does not have full range of motion and continues to have pain in the arm and shoulder. If there is no improvement in the next two months, he will return to the orthopedist and have an MRI done to evaluate the shoulder.
Fever 101.0; chills; fatigue, throwing up, soreness at injection site
11/19/21 pt had a positive COVID test (outpatient) at facility; 11/23/21 pt to ED with AHRF; right leg hematoma after a fall; given Decadron, Remdesivir, Baricitinib; pt became hypotensive in spite of vasopressors; hemorrhagic shock; transferred to ICU; pt's condition continued to deteriorate; pt chose comfort care and passed away in the hospital
Vaccinated pt tested positive for covid during hospital admission for tubal pregnancy. Vaccination was self reported and we have no information on type, location, date, etc for vaccine
arm  pain; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (arm  pain) in a 59-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concomitant products included LISINOPRIL, ROSUVASTATIN, METFORMIN, OMEPRAZOLE and OMEGA-3 FATTY ACIDS for an unknown indication, TAMSULOSIN.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (arm  pain). At the time of the report, PAIN IN EXTREMITY (arm  pain) had resolved. Second Dose AE      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter. Treatment information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 05-May-2021: TCR received. Second dose event reported.
pt exposed to varicella 2wk prior to developing vesicular rash;approx 10 lesions;dried up w/in a few days;
26 BF had Anthrax #2 on Thursday, 08/12/99 about 12:00 hrs. She had a little nausea on Thursday, 08/12/99. The pt developed swelling and itching of her LUE on Friday, 08/13/99. She denies fever. On Saturday, 08/14/99, she had a decreased appetite and nausea. She slept all Sunday 08/15/99. She had a 5 cm reaction to to Anthrax #1.
Incorrect vaccine for age--patient received first dose Moderna on April 1 at age 17; she received second dose Moderna on 5/1 in accordance with CDC guidance.  No AE.
COVID Breakthrough Case  Moderna Dose 1 4/8/21 (030B21A) Moderna Dose 2 5/6/21 (017C21A) COVID Positive 9/16/21  9/16/21: patient speaks limited language.  History is obtained with assistance of on-line interpretation services.  He presented to emergency department with worsening shortness of breath of 5 days duration. Gradually getting worse.  He came to hospital because he could not catch  breath.  Activity makes him more short of breath. His wife and daughter tested positive for SARS-CoV-2 last Monday.  He was found to be hypoxic with pulse ox of 56% on room air.  He also tested positive for SARS-CoV-2.  Chest x-ray showed bilateral lung infiltrates suggestive of viral pneumonitis.  He denied fever.  Denied nausea, vomiting or diarrhea.  Denied hemoptysis denied chest pain.  9/25/21: Patient was admitted on September 16, 2021 for evaluation of COVID pneumonia.  Patient was requiring high oxygen demand when he reached the ICU.  Pulmonology was consulted and he placed the patient on OptiFlow for a significant portion of his hospitalization.  For the patient's COVID management he received 5 days of remdesivir, 10 days of Decadron, 3 days of Levaquin.  The patient's hospitalization was complicated by persistent high oxygen demand.  A walk test for determination of home oxygen was performed prior to discharge and resulted in the patient requiring 2 L at all times.  Patient was unable to obtain home health due to his insurance status.
Symptoms varied over the course of 10+ days. -  Day 1-2: Piercing headache and  pain behind eyes that resulted in blurry vision for 20 minutes.  Pains in chest when inhaling deeply.  Pain and pressure behind knees.  Nausea. Persistent pain in flanks. - Day 3-7: Sever pain in stomach particularly immediately after eating.  Nausea, vomiting. Persistent pain in flanks. - Day 7-10: Pain in flanks, stomach pain, headaches and tenderness in left upper thigh  - Symptoms continue
Nose bleed lasting 3 days,throat and nose pain lasting 1 week, difficulty breathing lasting 3 days, persistent pain in neck and extending into head continues to date of this report, need to use 2 epipens for adverse reactions symptoms
This is a spontaneous report from a contactable pharmacist. A 69-year-old male patient received PREVNAR 13 (lot S35324, expiry date Aug2018, NDC number 00005-1971-02) on 06Sep2017, in left arm, at single dose, for immunization. Medical history and concomitant medications were not reported. Since 06Sep2017 the patient was having swelling in the arm where he received vaccination and pain. Since an unspecified date in Sep2017 he was not having any appetite. The reporter stated that the daughter of the patient thought the swelling would diminish but it did not, she described the swelling kept coming up and getting worse, not going down. The daughter of the patient stated that the patient's pain kept coming up. The patient has been using TYLENOL to treat pain. Reporter advised the daughter of the patient to add cold compress to it along with taking TYLENOL or MOTRIN to see if it helped and to call patient's primary care provider to let them know. Reporter explained that she has not seen the patient but from the way his daughter described the event, maybe swelling was medically significant. Reporter stated that pain was from a medically significant to disabling event. Reporter did not know the seriousness of appetite lost. Swelling had not resolved at the time of report. The outcome of the other events was unknown. Sender's Comments: Based on the information currently available, a contributory role of PREVNAR 13 towards the occurrence of "swelling in the arm where he received vaccination and pain" cannot be fully excluded considering the known adverse event profile of PREVNAR 13 and close time association.
Redness, swelling, tenderness and warmth for the last 48 hours since receiving pneumovax.
Swollen injection site. Stiff arm. Redness spreading. Cellulitis. Steroid antibody.
tiredness; headaches; having a lot of fever; This spontaneous case was reported by a physician (subsequently medically confirmed) and describes the occurrence of PYREXIA (having a lot of fever), HEADACHE (headaches) and FATIGUE (tiredness) in a 19-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Sep-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Sep-2021, the patient experienced PYREXIA (having a lot of fever), HEADACHE (headaches) and FATIGUE (tiredness). On 08-Sep-2021, PYREXIA (having a lot of fever), HEADACHE (headaches) and FATIGUE (tiredness) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were provided by the reporter. No treatment information was provided by the reporter.
Stated she rec'd the vaccine on Jan 23 & woke up on Jan 31st with a few bumps at the injection site. It progressed over the last couple days & is now the size of a soft-ball. Warm to touch. No pain. No itching. She F/U with her PCP @ Hospital today, 2-3-2021 by telemed appointment. She told her to call this health dept because it was our community clinic where she was vaccinated. Treating with claritin, benedryl, pepsin & an antibiotic now for 5 days. She is planning to get dose number 2 when due (per her PCP as well as HD recommendation)
Pt was given an expired MMRV vaccine at visit on 01/14/2019, as well as varicella vaccine. This visit, she was inadvertantly vaccinated with MMRV instead of plain MMR. We do not have any plain MMR VFC vaccines in stock and the MA that administered the dose thought the vaccine was the same as our private stock, which is plain MMR. The patient has now received 2 doses of Varicella, one expired MMRV, and one repeat dose of MMRV to cover the expired dose, resulting in over-vaccinating for varicella.
raised rash at injection site; raised rash at injection site; hot at injection site; This case was reported by a pharmacist via call center representative and described the occurrence of injection site erythema in a 71-year-old female patient who received Herpes zoster (Shingrix) (batch number 4M2C7, expiry date 19th December 2021) for prophylaxis.   The patient's past medical history included anaphylactic reaction (the patient has a history of anaphylactic reaction to bees.).   On 15th November 2019, the patient received the 1st dose of Shingrix. In November 2019, less than a week after receiving Shingrix, the patient experienced injection site erythema, injection site rash and injection site warmth. On an unknown date, the outcome of the injection site erythema, injection site rash and injection site warmth were unknown.   It was unknown if the reporter considered the injection site erythema, injection site rash and injection site warmth to be related to Shingrix.  Additional details were provided as follows: The patient received Shingrix on left arm. The patient received Shingrix and experienced a raised red hot rash at the injection site on her left arm that has been traveling up and down her arm over the last couple of days. The patient has a history of anaphylactic reaction to bees. The reporter consented to follow up.
Within 3 hours of receiving 3 vaccines, I began to feel a difference - lightheaded, chilled. After 5 hours I was alternately chilled and too hot, had a headache and became very nauseous. During the night, I awakened and had the sensation of floating ie. leaving my body with other visual hallucinations. Major symptoms were gone in AM but it took 3 days to completely feel better.
Mom noticed diffuse red, raised clusters of bumps around, but away from injection site on 10/13/2015 after she changed the Band-Aid.  On 10/14/2015 the clusters had come together forming large red, raised areas.
From the first vaccine injection to the last everything started going wrong with my daughter's menses. 1st shot, her periods wouldn't stop. 2nd shot, they stopped all together. 3rd shot, they started and didn't end until she was given Provera. Before her shots she had normal menses. Now my daughter is 20 and bleeds everyday. We've tried birth control of all kinds progesterone and estrogen She has been put on antidepressants and is anemic. She has been suicidal and definitely hormonal. We've been to multiple doctors and psychiatrists as well as a stay in a mental hospital. I reported the problems with each shot. The doctor's made light of my comments and I don't even know if they reported them.
NO ADVERSE REACTION.  Accidently given different vaccine. (Vaccine administration error). Patient had to get 2nd dose of Moderna from the outreach event in a local area. The patient got J&J vaccine by our staff on 5/13/21 at 1345. We monitored 15 mins. Patient did not have adverse events. We will contact the patient tomorrow to monitor.